Biotech Fuse Vectors secures $5.2M to advance cell-free gene therapy tech
Biotech Fuse Vectors secures $5.2M to advance cell-free gene therapy tech Fuse Vectors has raised $5.2M in pre-seed financing led by HCVC for its cell-free viral vector technology. The funding will accelerate the development of Fuse’s technology platform and pipeline of novel gene therapies. Fuse Vectors is a biotechnology company